Skip to main content
Premium Trial:

Request an Annual Quote

Quark Pharmaceuticals

In the Nov. 22 issue of RNAi News, Quark Pharmaceuticals’ investigational acute kidney injury drug AKIi-5 was incorrectly described as being licensed from Silence Therapeutics.
The drug candidate was actually developed by Quark. Its structure, however, is covered under intellectual property licensed by Quark from Silence.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.